Dehydroepiandrosterone (DHEA) against vaginal atrophy.

Trial Profile

Dehydroepiandrosterone (DHEA) against vaginal atrophy.

Phase of Trial: Phase III

Latest Information Update: 14 Jun 2017

At a glance

  • Drugs Prasterone (Primary)
  • Indications Atrophic vaginitis
  • Focus Therapeutic Use
  • Sponsors Endoceutics
  • Most Recent Events

    • 29 May 2012 Actual end date (May 2012) added as reported by
    • 29 May 2012 Actual patient number added 450 according to
    • 29 May 2012 Status changed from active, no longer recruiting to completed as reported by
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top